Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONITOR: Capivasertib in HR+/HER2- Metastatic Breast Cancer
NCT07802626Phase 3Not yet recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Oct 2026
- Primary completion
- Oct 2034
01
Overview
A Phase 3 trial of capivasertib in breast cancer, sponsored by SWOG Cancer Research Network. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07802626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07802626.